Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib + fulvestrant in EGFR-mutated advanced NSCLC after prior reversible EGFR TKI failure
NL-OMON37908Phase 2Active, not recruiting
- Sponsor
- VU University Medical Center
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib and fulvestrant in non-small cell lung cancer (NSCLC), sponsored by VU University Medical Center. Primary endpoint: No progression rate at 8 weeks. Started May 2012; status: active, not recruiting.
02
Drugs
gefitinibfulvestrant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON37908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37908.